argenx (NASDAQ:ARGX) Price Target Raised to $665.00

argenx (NASDAQ:ARGX - Get Free Report) had its price objective upped by research analysts at Guggenheim from $585.00 to $665.00 in a report released on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's price target would suggest a potential upside of 11.66% from the company's previous close.

A number of other brokerages also recently commented on ARGX. Raymond James reiterated a "strong-buy" rating and set a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft lowered argenx from a "buy" rating to a "hold" rating in a research report on Friday, October 4th. William Blair raised argenx from a "market perform" rating to an "outperform" rating in a research note on Friday. Robert W. Baird lowered shares of argenx from an "outperform" rating to a "neutral" rating and upped their price objective for the company from $515.00 to $650.00 in a research note on Friday. Finally, Truist Financial lifted their target price on shares of argenx from $540.00 to $660.00 and gave the stock a "buy" rating in a research report on Thursday. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $596.78.

argenx Trading Up 1.6 %

NASDAQ:ARGX traded up $9.28 during mid-day trading on Friday, reaching $595.58. 449,545 shares of the stock were exchanged, compared to its average volume of 309,272. The business has a fifty day moving average price of $537.88 and a 200 day moving average price of $464.29. argenx has a 1-year low of $327.73 and a 1-year high of $610.73. The firm has a market capitalization of $35.61 billion, a PE ratio of -680.98 and a beta of 0.63.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The company had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. During the same quarter in the previous year, the company posted ($1.25) EPS. On average, sell-side analysts forecast that argenx will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Profund Advisors LLC raised its stake in shares of argenx by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company's stock valued at $418,000 after acquiring an additional 28 shares in the last quarter. Wealth Alliance raised its position in shares of argenx by 4.8% in the second quarter. Wealth Alliance now owns 628 shares of the company's stock valued at $270,000 after purchasing an additional 29 shares during the period. GAMMA Investing LLC lifted its stake in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after buying an additional 40 shares during the last quarter. Toronto Dominion Bank boosted its holdings in shares of argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company's stock worth $119,000 after buying an additional 43 shares during the period. Finally, Sequoia Financial Advisors LLC grew its stake in argenx by 3.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company's stock valued at $737,000 after buying an additional 52 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.